Awakn Life Sciences Files Patent Cooperation Treaty (PCT) Application For The Treatment Of Behavioral Addictions May 26, 2022
Awakn Life Sciences CEO, Anthony Tennyson, Joins Dustin Robinson of Iter Investments for ‘The Investor… May 24, 2022
COMPASS Pathways presents largest ever study of psilocybin therapy, at American Psychiatric Association annual meeting May 23, 2022
Awakn Life Sciences Completes World’s First Ketamine Treatment Study for a Range of Behavioral Addictions May 19, 2022
Numinus Wellness Receives Health Canada Special Access Program Applicant Approval to Provide Psychedelic-assisted… May 16, 2022
MindMed Collaborators Prof. Liechti and Dr. Holze Announce Positive Topline Data from Phase 2 Trial Evaluating LSD in… May 11, 2022
